



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

1642  
15

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**11245/46604**

Application Number  
**09/840,146**

Filing Date  
**April 24, 2001**

Examiner  
**Holleran, A.L.**

Art Unit  
**1642**

Invention Title

**TREATMENT OF REFRACTORY HUMAN  
TUMORS WITH EPIDERMAL GROWTH FACTOR  
RECEPTOR ANTAGONISTS**

Inventor(s)  
**Harlan W. WAKSAL**


Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-  
1450 on

Date: October 1, 2003

By:

  
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00** to the deposit account of **KENYON & KENYON**, deposit account number **11-0600**. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Dated: October 1, 2003

By:

  
Kathryn M. Lumb  
(Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
**CUSTOMER NO. 26646**



**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT PTO-1449**

ATTY. DOCKET NO.  
**11245/46604**

SERIAL NO.  
**09/840,146**

APPLICANT  
**WAKSAL et al.**

FILING DATE  
**April 24, 2001**

GROUP  
**1642**

**U. S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,616,582	April 1, 1997	Barker			

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Moyer et al., "Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, in an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Res., Vol. 57, No. 21, November 1, 1997, pp. 4838-4848
	Pollack et al., "Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358, 774: Dynamics of Receptor Inhibition in Situ and Antitumor Effects in Athymic Mice", J. Pharmacol., Vol. 291, No. 2, November 1999, pp 739-748
	Rowinsky, et al., "Dose-Schedule-Finding, Pharmacokinetic (PK), Biologic, and Functional Imaging Studies of OSI-774, a Selective Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) Inhibitor", Abstract No. 5 (Presented at the 37 <sup>th</sup> Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001
	Anido et al., "Inhibition by ZD1839 (Iressa) of Epidermal Growth Factor (EGF) and Heregulin Induced Signaling Pathways in Human Breast Cancer Cells", Abstract No. 1712 (Presented at the 37 <sup>th</sup> Annual Meeting of ASCO), San Francisco, CA 12-15 May 2001
	Hidalgo et al., "Inhibition of the Epidermal Growth Factor Receptor (EGFR) by OSI-774, a Specific EGFR Inhibitor in Malignant and Normal Tissues of Cancer Patients", Abstract No. 281 (Presented at the 37 <sup>th</sup> Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.